Isryl-M 4 Forte Tablet PR contains a combination of Glimepiride 4 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus in patients whose hyperglycemia cannot be adequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glycemic control. The prolonged-release formulation ensures a steady release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Isryl-M 4 Forte Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet and lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or those undergoing radiologic studies involving iodinated contrast agents. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is essential during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability.